COVID-19 has evolved from an acute infectious disease into an enduring public-health and medical challenge. Although many people recover from the initial infection, others experience persistent symptoms, newly recognized medical conditions, or significant limitations in daily functioning.<\/p>\n\n\n\n
The COVID-19 Long-haul Foundation focuses on improving understanding of these continuing health problems through medical education, research analysis, scientific literature, and the identification of priorities for future investigation.<\/p>\n\n\n\n
Our work encompasses three related areas:<\/p>\n\n\n\n
Our objective is to help patients, caregivers, clinicians, researchers, and the public find relevant information and understand what current research establishes, what remains uncertain, and what needs to be investigated next.<\/p>\n\n\n\n
SARS-CoV-2 is an enveloped RNA virus belonging to the coronavirus family. It primarily spreads through respiratory particles and infects susceptible cells through interactions involving its spike protein and cellular receptors, including angiotensin-converting enzyme 2 (ACE2).<\/p>\n\n\n\n
Following infection, the body initiates innate and adaptive immune responses. These include inflammatory signaling, antibody production, and the activation of immune cells involved in recognizing and controlling infection.<\/p>\n\n\n\n
The severity and duration of illness vary substantially among individuals. Age, preexisting health conditions, immune status, prior immunity, viral characteristics, and other factors can influence clinical outcomes.<\/p>\n\n\n\n
The biological consequences of infection are not necessarily confined to the respiratory tract. Acute COVID-19 can affect multiple organ systems, and some individuals subsequently develop persistent or newly recognized health problems.<\/p>\n\n\n\n
Research continues to examine how viral characteristics, host responses, tissue injury, and other biological processes contribute to both acute disease and longer-term complications.<\/p>\n\n\n\n
Long COVID, also referred to as post-COVID condition or post-acute sequelae of SARS-CoV-2 infection, encompasses a heterogeneous group of health problems that continue or emerge after the initial infection.<\/p>\n\n\n\n
There is no single symptom pattern that defines every case. Some people experience relatively limited symptoms, while others develop disabling multisystem illness that substantially affects independence, employment, physical activity, and quality of life.<\/p>\n\n\n\n
The US Centers for Disease Control and Prevention describes Long COVID as an infection-associated chronic condition affecting one or more organ systems. Clinical assessment may rely on the patient’s history, physical examination, and appropriately directed testing. No single laboratory test currently establishes or excludes every case of Long COVID.<\/p>\n\n\n\n
Source: CDC \u2014 Long COVID Clinical Guidance<\/a>.<\/p>\n\n\n\n Neurological and cognitive symptoms<\/strong><\/p>\n\n\n\n Brain fog, impaired concentration, memory difficulties, headaches, dizziness, altered taste or smell, sleep disturbance, and other neurological complaints may persist following infection.<\/p>\n\n\n\n Fatigue and post-exertional malaise<\/strong><\/p>\n\n\n\n Some individuals experience profound fatigue or a worsening of symptoms after physical, cognitive, or emotional exertion. Post-exertional malaise can make conventional exercise-based rehabilitation inappropriate unless the individual’s symptoms and tolerance are carefully assessed.<\/p>\n\n\n\n Cardiovascular and autonomic symptoms<\/strong><\/p>\n\n\n\n Palpitations, orthostatic intolerance, altered heart-rate responses, exercise intolerance, and other symptoms can occur. These findings require appropriate evaluation because multiple conditions can produce similar manifestations.<\/p>\n\n\n\n Respiratory symptoms<\/strong><\/p>\n\n\n\n Persistent breathlessness, cough, reduced exercise capacity, and other respiratory problems may continue after the acute infection.<\/p>\n\n\n\n Musculoskeletal and systemic symptoms<\/strong><\/p>\n\n\n\n Muscle and joint pain, weakness, sensory disturbances, gastrointestinal symptoms, and other multisystem complaints have been reported. Individual symptoms may have several possible explanations and should not automatically be attributed to Long COVID without appropriate assessment.<\/p>\n\n\n\n There is no single established mechanism that explains every presentation. Research has investigated several potentially overlapping processes:<\/p>\n\n\n\n These mechanisms remain at different stages of scientific validation. Their importance may vary across patients, symptom patterns, and stages of illness.<\/p>\n\n\n\n The central research question is increasingly specific: which mechanisms operate in which patients, how can they be measured reliably, and can identifying them improve diagnosis or treatment?<\/p>\n\n\n\n Long COVID research continues to advance from broad descriptions of persistent symptoms toward more detailed investigation of biological subgroups, measurable outcomes, and treatment strategies.<\/p>\n\n\n\n Research published in Cell<\/em> in May 2026, highlighted by the National Institutes of Health, investigated antibodies that react with components of the human nervous system in people with Long COVID.<\/p>\n\n\n\n The investigators reported associations between particular autoantibody patterns and certain neurological symptoms. Experiments involving transferred antibodies in mice also produced findings relevant to pain, balance, and fatigue.<\/p>\n\n\n\n The results suggest that autoimmune mechanisms may contribute to neurological manifestations in a subset of patients. They do not establish that autoantibodies explain all Long COVID, nor do they establish a routine diagnostic test or proven treatment for the general patient population.<\/p>\n\n\n\n Further research should determine how reproducible these findings are, whether particular biomarkers can identify clinically meaningful subgroups, and whether treatments directed at these mechanisms improve patient outcomes.<\/p>\n\n\n\n Source: NIH \u2014 Immune system may attack nervous system in some Long COVID patients<\/a>.<\/p>\n\n\n\n RECOVER research reported in September 2026 examined physical activity and cardiopulmonary fitness among participants with different burdens of Long COVID symptoms.<\/p>\n\n\n\n The findings indicated that participants with a higher symptom burden tended to have less physical activity, higher resting heart rates, lower heart-rate variability, and lower measures of physical fitness.<\/p>\n\n\n\n These observations underscore the importance of measuring functional outcomes alongside individual symptoms. They also raise questions about the contributions of underlying disease, autonomic dysfunction, reduced activity, and deconditioning.<\/p>\n\n\n\n Future studies should distinguish these mechanisms and determine which interventions improve function without provoking post-exertional symptom exacerbation.<\/p>\n\n\n\n Source: RECOVER \u2014 Research Update, September 2026<\/a>.<\/p>\n\n\n\n A randomized, multicenter phase 3 trial of an integrated care pathway for Long COVID, published in Nature Medicine<\/em> in July 2026, evaluated multidisciplinary care in clinical settings.<\/p>\n\n\n\n The investigators reported that multidisciplinary holistic care was associated with reduced fatigue, although differences for other outcomes were modest. The results support continued investigation of coordinated clinical care and selected rehabilitation approaches, rather than assuming that one treatment will benefit every patient.<\/p>\n\n\n\n Further trials are needed to establish which interventions are most effective, for which patients, and under what clinical circumstances.<\/p>\n\n\n\nCommon clinical manifestations<\/h5>\n\n\n\n
What causes Long COVID?<\/h5>\n\n\n\n
\n
3. Important Research Developments in 2026<\/h5>\n\n\n\n
Neurological symptoms and autoantibodies<\/h5>\n\n\n\n
Long-term physical function and cardiopulmonary fitness<\/h5>\n\n\n\n
Integrated care and treatment research<\/h5>\n\n\n\n